To evaluate the clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries, we performed a prospective observational study of 233 cases of adult pneumococcal pneumonia in 9 Asian countries from January 2000 to June 2001. Among 233 isolates, 128 (55%) were not susceptible to penicillin (25.3% were intermediately susceptible, and 29.6% were resistant). Clinical severity of pneumococcal pneumonia was not significantly different between antibiotic-resistant and antibiotic-susceptible groups. Mortality rates among patients with pneumococcal pneumonia caused by penicillin-, cephalosporin-, or macrolideresistant strains were not higher than those with antibiotic-susceptible pneumococcal pneumonia. Bacteremia and mechanical ventilation were significant risk factors for death, but any kind of antibiotic resistance was not associated with increased mortality due to pneumococcal pneumonia. Outcome of pneumococcal pneumonia was not significantly affected by drug resistance, and current antimicrobial regimens are mostly effective in the treatment of pneumococcal pneumonia, despite the widespread emergence of in vitro resistance.
antibiotic resistance among S. pneumoniae has become a serious clinical concern [1, 2] . Although the prevalence of resistance varied among antimicrobial agents and countries, rapid escalation of antimicrobial resistance to penicillin, other b-lactam agents, and macrolides has been reported from many parts of the world during the previous 2 decades [3] [4] [5] [6] . In some Asian countries in particular, the reported prevalence of penicillin and macrolide resistance was the highest in the world [7] [8] [9] . With the increasing prevalence of in vitro resistance to multiple antibiotics among S. pneumoniae, questions and concerns about the clinical impact of resistance have been raised. Treatment failure associated with antibiotic-resistant pneumococci has been reported for patients with otitis media and meningitis, although the clinical significance of antimicrobial resistance for patients with pneumococcal pneumonia remains controversial [10] . Previous data indicated that low-level resistance to penicillin or cephalosporins did not affect the clinical outcome of pneumococcal pneumonia [11] [12] [13] , whereas high-level resistance to these b-lactam agents could increase mortality due to pneumococcal pneumonia [14] . Failures of macrolide antibiotic treatment in cases of pneumonia [15] or bacteremia [16] due to erythromycin-resistant S. pneumoniae were also reported. Recent reports have documented the therapeutic failures of fluoroquinolone treatment in patients with pneumococcal pneumonia [17] .
Because of the frequency and importance of S. pneumoniae in community-acquired pneumonia, the clinical relevance of the increasing prevalence of resistance among pneumococcal isolates in relation to the antimicrobials currently used to treat pneumonia should be clarified. To evaluate the clinical features and final outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains, the Asian Network for Surveillance of Resistant Pathogens (ANSORP) conducted a prospective multinational study in Asia.
PATIENTS AND METHODS
Participating centers. The following 9 medical centers in the ANSORP Study Group participated in the study: Samsung Medical Center (Seoul, Korea), Princess Margaret Hospital (Hong Kong), Chulalongkorn University (Bangkok, Thailand), Chang Gung Memorial Hospital (Taipei, Taiwan), Christian Medical College (Vellore, India), University of Colombo (Colombo, Sri Lanka), National University of Singapore (Singapore), University Malaya (Kuala Lumpur, Malaysia), and Research Institute of Tropical Medicine (Manila, The Philippines) (table 1) .
Patients with pneumococcal pneumonia. All consecutive cases of community-acquired pneumococcal pneumonia in adult patients (age, у18 years) diagnosed between January 2000 and June 2001 were prospectively enrolled at 9 study centers in Asia. Patients were enrolled only if all of the following findings were present: clinical symptoms and signs of pneumonia, such as fever, cough, and sputum; a distinct pulmonary infiltrate revealed on a chest radiograph; and isolation of S. pneumoniae from sterile specimens (blood or pleural fluid) and/or from lower respiratory tract specimens with compatible Gram stain findings. Investigators at each participating center evaluated the eligibility of the cases. Patients who did not receive a diagnosis of pneumonia within 48 h after hospital admission, who did not complete the follow-up schedule, or who had inadequate specimens as the only available source of isolates were excluded from the study.
Data collection. We recorded the following data on a standardized case report form: baseline information, including sociodemographic characteristics, underlying conditions, history of antibiotic use within the 3 months before presentation to the hospital, clinical manifestations, laboratory results, chest radiographic findings at presentation, antimicrobial therapy, clinical course, and death; underlying conditions, such as bronchopulmonary diseases, smoking, cerebrovascular disease, malignancy, diabetes mellitus, chronic renal disease, chronic liver disease, corticosteroid use, asplenia, and transplantation; and clinical and laboratory features, including vital signs at presentation, alteration in mental status, hypoxemia (arterial O 2 pressure, !60 mm Hg), WBC count, hematocrit, blood urea nitrogen level, serum creatinine level, blood glucose level, pH of arterial blood, and results of blood cultures at initial presentation to the hospital were recorded for all patients. On the basis of these parameters, clinical severity of pneumococcal pneumonia was assessed by means of the Pneumonia Severity Index (PSI), as proposed by Fine et al. [18] . Patients were classified into risk classes of 1-5 on the basis of the PSI score.
Mortality was defined to include all deaths within 30 days after the diagnosis of pneumonia.
Antimicrobial susceptibility testing of 233 isolates was performed using the broth microdilution test at a central laboratory (Samsung Medical Center, Korea), according to NCCLS guidelines [19] . The following 14 antimicrobial agents were tested: penicillin, amoxicillin-clavulanate, cefuroxime, ceftriaxone, erythromycin, azithromycin, clarithromycin, clindamycin, ciprofloxacin, levofloxacin, moxifloxacin, gatifloxacin, doxycycline, and trimethoprim-sulfamethoxazole. S. pneumoniae ATCC 49619 was used as a control. We used susceptibility interpretive criteria found in NCCLS approved standard M100-S13 [20] . The NCCLS M100-S13 guidelines include new interpretive susceptibility criteria for nonmeningeal isolates of S. pneumoniae, with MICs of ceftriaxone р1 mg/L (susceptible), 2 mg/L (intermediately susceptible), and у4 mg/L (resistant). For the purpose of the present study, ciprofloxacin MICs of у4 mg/L were used to define the resistance category.
Data analysis. Statistical analysis was performed using SPSS, version 9.0 for Windows NT (SPSS). Clinical manifestations and disease severity were compared between antibioticsusceptible and antibiotic-resistant strains with regard to penicillin, cefuroxime, erythromycin, and levofloxacin using Student's t test, Fisher's exact test, or x 2 analysis. Crude mortality rates within 30 days after diagnosis were obtained for all patients and for patients with severe pneumonia (PSI class 4/ 5). ORs and 95% CIs of mortality associated with pneumococcal pneumonia were calculated by unconditional logistic regression models. Multivariate odds ratios (mORs) to analyze the risk factors were adjusted for antibiotic resistance, comorbidities, and disease severity.
To evaluate the direct impact of antimicrobial resistance on medical outcomes, the concordance of antimicrobial therapy administered within the first 48 h of treatment was assessed for patients with antibiotic-nonsusceptible pneumococcal pneumonia. Antimicrobial regimens were classified as concordant therapy when the patient received у1 antibiotic during the first 48 h of treatment to which a pneumococcal isolate was fully susceptible. Antimicrobial regimens were classified as discordant therapy when the patient did not receive any single antibiotic during the first 48 h of treatment to which the pneumococcal isolate was susceptible or intermediately susceptible, regardless of the modification of the antibiotic regimen after 48 h. was considered to be statistically significant. P ! .05 The initial antibiotic regimen provided to the patients varied by country, with the most commonly administered antibiotics being penicillin (India and Sri Lanka), amoxicillin-clavulanate (Hong Kong), second-generation cephalosporins (Malaysia), third-generation cephalosporins (Taiwan and Singapore), and second-generation cephalosporins plus macrolides (Korea).
RESULTS

Patient characteristics.
In vitro susceptibility of infecting pathogens. Of the 233 isolates of S. pneumoniae, 128 (55%) were not susceptible to penicillin (25.3% were intermediately susceptible and 29.6% were resistant) (table 2). MICs of penicillin were 0.008-4 mg/L, and the MIC 90 was 2 mg/L. On the basis of the nonmeningeal breakpoint for resistance to ceftriaxone (MIC, у4 mg/L), only 1 isolate was fully resistant to ceftriaxone. Multivariate analysis did not identify any significant risk factors for acquiring penicillin resistance. More than one-half of the isolates were not susceptible to erythromycin (1.3% were intermediately susceptible, and 52.4% were resistant), with very high-level resistance. MICs 90 of erythromycin, azithromycin, and clarithromycin were 132 mg/L. Age у50 years (mOR, 2.8; 95% CI, 1.1-7.1) and cefuroxime resistance (mOR, 7.9; 95% CI, 2.4-26.1) were independent risk factors for erythromycin resistance. Rate of resistance to ciprofloxacin (MIC, у4 mg/L) was relatively high (9.6%), especially among isolates from Hong Kong, whereas resistance to levofloxacin (4.3% of isolates), moxifloxacin (0.4%), and gatifloxacin (0.4%) were low at the time of the study. Resistance to doxycycline and trimethoprim-sulfamethoxazole was also high (50.2% and 47.8% of isolates, respectively).
Impact of resistance on clinical features and severity. Mean age (‫ע‬SD) was significantly higher among patients with penicillin-nonsusceptible strains ( years) and pa-64.5 ‫ע‬ 16.4 tients with penicillin-resistant strains ( years) than 66.6 ‫ע‬ 15.5 among those with penicillin-susceptible strains (56.3 ‫ע‬ 17.7 years) ( ). In general, vital signs and abnormal laboratory P ! .01 findings at the time of presentation in patients infected with penicillin-nonsusceptible strains (i.e., intermediately susceptible and resistant strains with MICs у1 mg/L) or penicillinresistant strains (MIC, у2 mg/L) were not significantly different from those in patients infected with penicillin-susceptible strains (table 3) . However, pleural effusion ( ) and bac-P p .008 teremia ( ) were significantly more frequent among pa-P ! .001 tients infected with penicillin-susceptible strains, whereas low arterial blood pH was more common in patients with penicillinresistant strains than in patients with penicillin-susceptible strains ( ). Duration of fever was not different in any P p .01 groups. Mean pneumonia severity-of-illness scores (‫ע‬SD) based on PSI calculations at the time of enrollment were higher among patients with penicillin-nonsusceptible strains (90.9 ‫ע‬ 30.9;
) and patients with penicillin-resistant strains P p .03 (98.2 ‫ע‬ 31.6; ) than among those with penicillin-sus-P p .002 ceptible strains ( ). The proportion of patients in the 81.1 ‫ע‬ 36.1 2 highest severity-of-illness categories (PSI risk classes, 4/5) in the penicillin-nonsusceptible group (57 of 128 patients) was not significantly different from that in the penicillin-susceptible group (35 of 105 patients) (
). However, patients in-P p .08 fected with penicillin-resistant strains (MIC of penicillin, у2 mg/L) were more frequently associated with PSI risk classes 4/ 5 than were those with penicillin-susceptible strains (OR, 2.6; 95% CI, 1.3-5.1;
).
Comparison between erythromycin-susceptible and -resistant groups revealed that metabolic acidosis (arterial blood pH !7.35) was more frequent in the resistant group (OR, 3.14; 95% CI, 1.55-6.41; ), whereas bacteremia (OR, 0.5; 95% P ! .001 CI, 0.3-0.9;
) and pleural effusion (OR, 0.4; 95% CI, P p .01 0.2-0.9; ) were more frequent in patients with eryth-P p .02 romycin-susceptible pneumonia ( ). Microbiological eradication was P ! .01 documented in 92 patients (39.5%), but 6 (2.6%) exhibited persistent growth of bacteria despite antibiotic treatment. However, 135 patients (57.9%) were not evaluated with regard to the microbiological outcome, as a result of lack of or inability to perform follow-up cultures.
Of the 233 patients with pneumococcal pneumonia, mortality among patients infected with penicillin-susceptible strains (12.4%) was not different from that among patients with penicillin-nonsusceptible strains (14.1%), penicillin-resistant strains (15.9%; MIC, у2 mg/L), or high-level resistant strains (13.6%; MIC, 4 mg/L). Of the 74 patients who had more-severe illness (PSI class 4/5), mortality was similar among those with penicillin-susceptible strains (20%) and those with penicillinnonsusceptible strains (28.2%) (OR, 1.5; 95% CI, 0. 4-5.3; ). Pneumonia caused by cefuroxime-resistant strains P p .4 (16.1% of cases) resulted in mortality similar to that associated with cefuroxime-susceptible strains (11.5% of cases) (OR, 1.4; 95% CI, 0.6-3.4; ) (table 5) . P p .3 Mortality among patients with erythromycin-resistant pneumonia (16.1%) was not statistically different than that among patients with erythromycin-susceptible pneumonia (12%) (OR, 1.4; 95% CI, 0.5-3.3; ) (table 5) . Pneumococcal pneu-P p .6 monia caused by a stain with high-level erythromycin resistance (MIC, у64 mg/L) also resulted in similar mortality among patients with erythromycin-susceptible pneumonia (data not shown). Mortality was comparable between patients in the erythromycin-susceptible and erythromycin-resistant groups with PSI class 4/5 pneumonia (OR, 1.0; 95% CI, 0.3-3.5;
). P p .9 Of the 233 patients with pneumococcal pneumonia, 127 were infected by multidrug-resistant strains (i.e., strains with resistance to agents from у3 antibiotic classes), and 32 patients were infected with strains that were susceptible to all antimicrobial agents tested. Comparison of mortality between these 2 groups showed that multidrug resistance did not affect mortality due to pneumococcal pneumonia (mortality, 14.9% in the multidrug-resistant group vs. 15.6% in the "all-susceptible" groups; OR, 0.9; 95% CI, 0.3-3.2; ) P p 1.0
Impact of discordant antimicrobial therapy on mortality.
A total of 207 patients were evaluated for mortality with respect to the concordance of their antimicrobial therapy. One hundred seventy patients (82.1%) received a concordant regimen, whereas 37 (17.9%) did not receive any antimicrobial agent to which an infecting pathogen was susceptible in vitro. Mortality among patients who received discordant therapy was less than that among patients who received concordant therapy (5 [13.5%] of 37 vs. 24 [14. 1%] of 170 patients) (OR, 0.9; 95% CI, 0.3-2.6;
). Discordant therapy in terms of resistance P p .9 to specific antimicrobial agents also did not result in increased mortality. Mortality associated with penicillin discordance (6 [25%] of 24 patients) was less than that associated with penicillin concordance (6 [28.6%] of 21 patients) (OR, 0.8; 95% CI, 0.2-3.1;
). Also, discordant therapy involving ce-P p .78 furoxime and erythromycin did not result in increased mortality (table 5) . Discordant antimicrobial therapy did not result in increased mortality among 72 patients with bacteremic pneumococcal pneumonia (data not shown).
Risk factors for mortality associated with pneumococcal pneumonia. Univariate analysis of risk factors showed that underlying lung diseases, malignancy, chronic renal disease, altered mental status at presentation, hypotension, leukopenia, anemia, uremia, bacteremia, and mechanical ventilation were significant risk factors for death among patients with pneumococcal pneumonia (data not shown). However, when multivariate analysis was used to compare the relative contribution of the factors associated with mortality, only bacteremia (OR, 10.5; 95% CI, 2.9-37.8; ) and mechanical ventilation P ! .01 (OR, 12.5; 95% CI, 3.6-42.9;
) were significant risk fac-P ! .01 tors for death among patients with pneumococcal pneumonia (table 6). Antimicrobial resistance of any kind among the infecting pathogens was not associated with increased mortality among patients with pneumococcal pneumonia.
DISCUSSION
Lower respiratory tract infections remain the leading cause of death in developing countries and the fourth leading cause of death in developed countries [21] . Because S. pneumoniae is obviously the most common pathogen associated with community-acquired pneumonia, clinical implications of antimicrobial resistance in S. pneumoniae are critical in clinical practice.
With regard to the severity of pneumonia, our data showed that infection with penicillin-resistant or erythromycin-resistant S. pneumoniae strains did not result in more-severe illness than that associated with infection due to strains susceptible to either antibiotic, although higher mean PSI score and higher numbers of patients with PSI class 4/5 pneumonia were observed in the antimicrobial-resistant groups. The main reason for the higher mean PSI score and the higher number of patients with class 4/ 5 illness in the antibiotic-resistant group was the significantly higher age of patients in this group. Previous reports also suggest that the clinical severity of pneumonia is not affected by antibiotic resistance [11] [12] [13] , although one recent report documented more-severe illness and more-frequent suppurative complications in patients with bacteremic pneumococcal pneumonia caused by penicillin-nonsusceptible strains [22] .
The 30-day crude mortality of 13.3% among all patients with pneumococcal pneumonia in this study was comparable with that in other reports [11, 14, 18] . It is believed that bacteremia is documented in ∼20% of patients hospitalized for pneu- mococcal pneumonia [23] . However, in our study, 30% of patients with pneumococcal pneumonia had blood cultures positive for S. pneumoniae. Also, the proportion of patients with severe pneumonia (PSI class 4/5) was 40%, which was much higher than in other reports [18] . Because all participating centers in our study were tertiary care hospitals in urban areas, patients with pneumococcal pneumonia could have had moresevere illness than those in the general population. In our study, the case fatality rate for bacteremic pneumococcal pneumonia was 31.9%, which is comparable with rates of 7%-35% reported elsewhere [24] [25] [26] . Data from our study suggest that the 30-day crude mortality associated with pneumococcal pneumonia was not affected by penicillin resistance, regardless of severity of illness or level of resistance. The mean PSI score and the proportion of patients with PSI class 4/5 illness, which were significantly higher among patients infected with penicillin-resistant strains, did not have direct association with increased overall mortality. When we mutually adjusted risk factors for mortality, only the presence of bacteremia and the use of mechanical ventilation sustained a significant association with mortality. Although PSI class 4/ 5 illness was significantly associated with death in univariate analysis, it was not significant in multivariate analysis, probably because of the lack of power. Mortality among 69 patients infected with strains that were highly resistant to penicillin (MIC, у2 mg/L, including MICs of 4 mg/L for 22 strains) was also not different from that in the group with penicillinsusceptible strains, regardless of the clinical severity of illness.
Previous reports suggest that the current level of resistance to penicillin and cephalosporins among S. pneumoniae strains is not associated with increased mortality among patients with pneumococcal pneumonia [11] [12] [13] . In contrast, Feikin et al. [14] have reported that mortality was significantly associated with MICs of penicillin and cefotaxime of у4 and у2 mg/L, respectively, when deaths during the first 4 hospital days were excluded. However, this study did not include data on antimicrobial therapy, and, therefore, the impact of discordant therapy on mortality could not be assessed. A recent report showed that discordant therapy for patients with pneumococcal bacteremia caused by cefuroxime-resistant strains resulted in increased mortality [27] . Our data show that discordant therapy with penicillin or cefuroxime did not result in increased mortality among patients with pneumococcal pneumonia, regardless of the presence of bacteremia. These data are consistent with those in previous reports [12, 22] .
One of the most remarkable findings from our study was the very high prevalence and level of resistance to macrolides, such as erythromycin, azithromycin, and clarithromycin, in S. pneumoniae from Asian countries. Because most previous studies have focused on the impact that penicillin resistance has on pneumococcal pneumonia, relevant data on the impact that macrolide resistance has on pneumococcal pneumonia are lacking. Recently, clinical failures of macrolide therapy have been reported in patients with pneumococcal pneumonia or bacteremia caused by macrolide-resistant strains [15, 16] . These data suggested that in vitro macrolide resistance-either lowlevel resistance due to the efflux mechanism or high-level resistance due to the methylase mechanism-is clinically relevant. However, our data show that mortality among patients with erythromycin-resistant strains was not significantly different from that among patients with erythromycin-susceptible strains. Although there was no difference in mortality, in vitro susceptibility data for macrolide-resistant strains recovered from patients with pneumococcal pneumonia in Asian countries should be an important consideration for selecting an empirical therapeutic option for treatment of communityacquired pneumonia. In many Asian countries, the ermB gene is found in 150% of pneumococcal isolates, either alone or in combination with the mefA gene, and the level of erythromycin resistance is very high, with MICs 90 1128 mg/L [28] .
There are some limitations to our study. First, mortality may be a relatively insensitive measurement of the impact of drug resistance in community-acquired pneumonia [10] . Furthermore, because data on attributable mortality or early death within 7-14 days after the onset of pneumococcal pneumonia was not available from the data, we could not evaluate the direct impact of resistance on early clinical outcome. Second, all patients in this study were enrolled at tertiary care centers in urban areas, and the number of patients from each participating center was relatively small. Therefore, current data do not represent the overall status of the clinical characteristics or the final outcome associated with pneumococcal pneumonia in each country. Because the main purpose of this study was to evaluate the clinical impact of antimicrobial resistance in pneumococcal pneumonia, all cases of pneumococcal pneumonia in different geographic regions were collectively analyzed. However, differences in the disease severity and the quality of clinical care in different centers could have affected the final outcome of pneumonia. Third, although our data showed that discordant therapy did not result in increased mortality among patients with pneumococcal pneumonia regardless of the type of antimicrobial resistance among infecting isolates, the number of patients with discordant therapy (particularly patients with bacteremic pneumococcal pneumonia) was relatively small. Because recent data on macrolide discordance documented increased mortality associated with invasive pneumococcal diseases, further studies involving more patients who received discordant therapy are warranted. In summary, data from the first multicenter, prospective, observational study of pneumococcal pneumonia in Asian countries suggest that penicillin, cephalosporin, or macrolide resistance in S. pneumoniae may not affect mortality associated with pneumococcal pneumonia. Data suggest that current antimicrobial regimens are still effective in the treatment of pneumococcal pneumonia, despite the widespread emergence of in vitro resistance in S. pneumoniae. Because of the continuous increase in the level of resistance to penicillin, other b-lactam agents, and macrolides among pneumococcal isolates in many parts of the world, further clinical studies involving increased numbers of patients with highly resistant strains are warranted to evaluate the clinical impact of in vitro resistance.
